Paratek Pharmaceuticals (PRTK) Lowered to “Strong Sell” at BidaskClub
Paratek Pharmaceuticals (NASDAQ:PRTK) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday.
Several other brokerages have also issued reports on PRTK. Guggenheim initiated coverage on Paratek Pharmaceuticals in a report on Tuesday, October 24th. They set a “buy” rating and a $44.00 price target for the company. Robert W. Baird restated a “buy” rating and issued a $40.00 target price on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. Cantor Fitzgerald restated a “buy” rating and issued a $50.00 target price on shares of Paratek Pharmaceuticals in a report on Thursday, September 21st. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 1st. Finally, ValuEngine lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 18th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $40.00.
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded down $0.20 during trading on Friday, hitting $18.65. The stock had a trading volume of 554,971 shares, compared to its average volume of 338,396. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.53 and a quick ratio of 10.53. Paratek Pharmaceuticals has a fifty-two week low of $12.90 and a fifty-two week high of $29.00.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.